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The Dopamine Hypothesis of Schizophrenia is actively being challenged by the NMDA
Receptor Hypofunctioning Hypothesis of Schizophrenia.The latter hypothesis may actually
be the starting point in neuronal pathways that ultimately modifies dopamine pathways
involved in generating both positive and negative symptoms of schizophrenia postulated
by the former hypothesis.The authors suggest that even this latter, NMDA receptor-based,
hypothesis is likely too narrow and offer a review of typical glutamate and dopamine-based
neurocircuitry, propose genetic vulnerabilities impacting glutamate neurocircuitry, and pro-
vide a broad interpretation of a possible etiology of schizophrenia. In conclusion, there is a
brief review of potential schizophrenia treatments that rely on the etiologic theory provided
in the body of the paper.
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INTRODUCTION
Hypotheses for the origin of schizophrenia symptoms have likely
moved further than the original “Dopamine Hypothesis” where it
is postulated that overactive mesolimbic dopamine (DA) neurons
cause the positive symptoms of psychosis and the corollary that
underactive mesocortical DA neurons, cause the negative, cog-
nitive, and affective symptoms of schizophrenia. For more than
30 years, this key hypothesis has dominated theories of schiz-
ophrenia and is placed prominently in every psychiatric text-
book written today. This theory was reverse engineered based
initially upon observations that drugs that increase DA, such
as amphetamine and cocaine, can create psychotic symptoms,
whereas antipsychotic drugs that decrease DA by antagonizing
dopamine D2 receptors actually diminish psychotic symptoms
(Meltzer and Stahl, 1976). Figure 1 displays the overactivity of
mesolimbic DA circuitry as the basis for development of posi-
tive symptoms, and Figure 2 depicts the hypofunctioning of the
mesocortical DA pathway which projects to the frontal cortex
(Meltzer and Stahl, 1976; Stahl, 2007a). This hypofrontality is the
proposed mediator of negative, cognitive, and affective symptoms
of schizophrenia.
The Dopamine Hypothesis of Schizophrenia has been accepted
as fact and antipsychotic medications have continued to be devel-
oped based upon the mechanism of antagonizing D2 receptors
in hopes of lowering the firing and activity of the mesolimbic
DA pathway. Clinicians from the 1950s onward were able to use
the typical antipsychotics that were first developed from phenoth-
iazine chemical structures and then utilized other chemical classes,
i.e., butyrophenones, thioxanthenes, etc., as antipsychotic agents.
In the 1990s, the atypical antipsychotics were developed, branded,
and marketed with a dual serotonin-dopamine receptor antago-
nism (SDA) mechanism of action whereby they simultaneously
block both D2 and serotonin-2A (5HT-2A) receptors allowing
for adequate antipsychotic effectiveness while lowering the risk of
extrapyramidal syndromes (EPS). This improved neuromuscular
safety profile occurs as the 5HT-2A receptor antagonism allows
these novel agents to be more selective at dampening mesolimbic
DA activity while allowing less interference in the nigrostriatal DA
pathway (Stahl, 2007a; Opler and Opler, 2012).
Interestingly, from a clinician’s point of view it is not often
asked, “where did the excess dopamine activity come from?” Sim-
plistically, a schizophrenic might have too much DA production,
too little catabolism, too active or sensitive D2 receptors, etc. Schiz-
ophrenia therefore was postulated to be an illness based upon
the Stress-Diathesis Model (Sadock and Sadock, 2003; Straub and
Weinberger, 2006) where an individual likely has inherited one or
more genes that code for abnormal proteins, and these proteins
likely modify the way the mesolimbic DA pathway operates. The
net result is that these abnormal proteins, i.e., receptors, enzymes,
etc. likely impact upon the mesolimbic DA system making it hyper-
active resulting in psychotic symptom development (Stahl, 2007a).
This diathesis, or biological risk, also has to be paired with environ-
mental stress to create enough symptoms to warrant the syndromal
diagnosis of schizophrenia.
If schizophrenia developed only out of the handful of DA
related genes in the human genome, then researchers should be
able to create much more consistently and fully effective drugs for
treating positive and negative symptoms. After 60 years of research,
there are now likely safer antipsychotic medications, but they have
failed to become more effective overall. Thinking outside of the
box would suggest that there has to be more to the pathology of
schizophrenia than just DA neurons that project from the ventral
tegmental area (VTA) to the limbic structures of the brain. Per-
haps, elevated mesolimbic DA activity creates one form, or type
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FIGURE 1 |The Dopamine Hypothesis suggests quite simply that normal,
baseline mesolimbic dopamine output yields normal psychiatric
functioning (A) but the positive symptoms of schizophrenia are a direct
result of too much DA neuronal firing originating in the midbrain and
allowing excessive DA release and activity in limbic structures (B; Stahl,
2008).
FIGURE 2 | A corollary of the original Dopamine Hypothesis suggests
that normal psychiatric functioning occurs as a result of baseline or
normal dopamine output reaching the frontal cortex (A), but the
negative symptoms of schizophrenia are a direct result of too little DA
neuronal firing originating in the midbrain and allowing poor DA release
and activity the frontal cortex (B; Stahl, 2008).
of schizophrenia? Patients with “dopamine sensitive schizophre-
nia” can be cured and have symptom remission on the available
antipsychotic agents. Clinically, like a patient with breast cancer
who undergoes genetic testing to determine if her cancer is estro-
gen sensitive or not, a schizophrenic could be genetically analyzed
to see where his genetic vulnerability lies. If this diathesis happens
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to be in the DA mesolimbic system, then he statistically should
respond very well to any of the marketed antipsychotics. If this
schizophrenic patient is not positive for DA risk genes, then he is
likely to have treatment resistant or refractory schizophrenia when
treated with the available antipsychotic agents.
The oversimplification dictated by the Dopamine Hypothe-
sis and the less than stellar clinical remission outcomes with D2
receptor antagonizing antipsychotics would suggest that either DA
hyperactivity is only one part of the etiology and onset of schiz-
ophrenia, or perhaps it is the final common pathway whereby
stress and multiple other neurotransmitters, receptors, neuronal
pathways, etc. have to become jeopardized and converge on the
mesolimbic system allowing DA hyperactivity to finally ensue.
It is possible that some schizophrenia patients have normal DA
pathways and their symptoms originate in other neuroanatomic
structures that function primarily under the influence of non-DA
neurotransmitters.
In this manner, the NMDA Receptor Hypofunction Hypothe-
sis, has garnered much research and writing. Here, a faulty series of
NMDA glutamate (GLU) receptors located on gamma aminobu-
tyric acid (GABA) interneurons are purported to ultimately allow
the generation of excessive mesolimbic DA activity outlined in the
original Dopamine Hypothesis (Stahl, 2007a). This GLU variable
now increases the etiologic complexity regarding development of
schizophrenia symptoms as there is now interplay between GLU,
GABA, and DA neurotransmitters. There is also neuroanatomic
complexity in that the GLU neurons originate in the frontal cor-
tex but descend into the limbic structures to exert their control
over DA functioning. Now, to develop schizophrenia, a patient
might have to inherit vulnerable genes in the DA, GLU, or even
GABA-based neuronal systems. This fact would indicate that new
approaches geared toward developing new treatments for schizo-
phrenia would necessarily have to begin a divergence away from
mastering D2 receptor antagonism pharmacodynamically, and
move toward agents with other mechanistic properties.
This paper will now focus, not only on the NMDA Receptor
Hypofunctioning Hypothesis of schizophrenia, but more glob-
ally investigate how a faulty glutamatergic system may impact
neuropsychiatric function and possibly be related to the onset of
positive and negative symptoms of schizophrenia.
NEUROANATOMIC PRIMER: GLUTAMATE, GABA, AND
DOPAMINE CIRCUITS
The rest of this paper and understanding of its theories necessitates
understanding some basic neuronal pathways in a very simplis-
tic form. Figure 3 depicts a series of GLU neurons that begin in
FIGURE 3 | Five glutamate pathways. (a) The cortical brainstem glutamate
projection is a descending pathway that projects from cortical pyramidal
neurons in the prefrontal cortex to brainstorm neurotransmitter centers
(raphe, locus coeruleus, ventral tegmental area, substantia nigra) and
regulates neurotransmitter release. (b) Another descending glutamatergic
pathway projects from the prefrontal cortex to the striatum (corticostriatal
glutamate pathway) and to the nucleus accumbens (cortico-accumbens
glutamate pathway), and constitutes the “corticostriatal” portion of
cortico-striatal-thalamic loops. (c) Thalamocortical glutamate pathways are
pathways that ascend from the thalamus and innervate pyramidal neurons in
the cortex. (d) Corticothalamic glutamate pathways descend from the
prefrontal cortex to the thalamus. (e) Intracortical pyramidal neurons can
communicate with each other via the neurotransmitter glutamate. These
pathways are known as cortico-cortical glutamatergic pathways. Three of the
five pathways project from the frontal cortex and penetrate into deeper brain
areas where they exert control over the neuroanatomic structures residing
there. This paper will focus on the descending circuits associated with (a) and
(b) predominantly (Stahl, 2008).
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the frontal cortex and connect and project in to brainstem, mid-
brain, and limbic areas. In this way, neurons originating in the
more modern frontal neocortex may penetrate into deeper areas
of the brain to exert control over midbrain centers that are pri-
marily responsible for creating and projecting neurotransmitter
activity that are ultimately responsible for drive and affective initi-
ation. These primary GLU neurons may project further to deeper
brain areas such as the amygdala and nucleus accumbens creating
appropriate perceptual balance versus psychosis. This simple cir-
cuitry will be the basis for understanding the onset of negative and
positive symptoms of schizophrenia.
In order to focus on the development of positive psy-
chotic symptoms, the cortical brainstem glutamate projection
(Figure 3 (a)) must be examined more closely in its normal func-
tioning state (Figure 4A) and its abnormal state (Figure 4B) as far
as schizophrenia symptom development is concerned.
As outlined in Figures 4A,B below, DA neuronal activity orig-
inating in the midbrain and limbic structures does not exist in a
vacuum and is likely controlled by GLU neurons in the frontal cor-
tex to a great extent. Strong cortical primary neuronal GLU firing
creates a circuit where strong GABA interneuron tone next occurs
thus dampening secondary cortical GLU neuronal tone. This loss
of GLU tone which arrives at the origin of the DA mesolimbic
pathway can lower DA neuronal firing which is actually the normal
state (homeostasis) and allows for normal psychiatric functioning.
The excess DA from the Dopamine Hypothesis might actually be
derived from the GLU neurocircuitry system. The NMDA Recep-
tor Hypofunctioning Hypothesis suggests that NMDA receptors
attached to the GABA interneurons situated between the primary
and secondary GLU cortical neurons are to blame. These defective,
insensitive NMDA receptors do not receive adequate stimulation
from the primary GLU neuron thus making the GABA interneuron
less effective, firing less often. This loss of GABA output onto the
secondary GLU neuron allows it to fire more often, directly causing
the firing of more and excessive DA (the Dopamine Hypothesis)
neurons in the mesolimbic pathway resulting in psychotic symp-
toms. This makes the GLU-GABA-GLU-DA circuit complete, but
now abnormal in functioning. The theoretical neuroanatomic cir-
cuitry involved in the Dopamine Hypothesis and the Glutamate
Hypothesis has previously been briefly reviewed by one of the
authors (Stahl, 2007a,b, 2008) and the genetic underpinnings of
the Glutamate Hypothesis by both (Schwartz et al., 2012). Further
FIGURE 4 | (A) Normal GLU-GABA-GLU-DA Neuronal Circuitry. The cortical
brainstem glutamate projection starts in the frontal cortex as the top most
neuron and leads ultimately to the deeper mesolimbic dopamine pathway.
However, this sequence of neurons consists of several stops making a
neurocircuit loop. Normally, a fully functioning primary GLU neuron (top
most pyramidal neuron) fires upon a smaller GABA interneuron which next
releases inhibitory GABA onto a secondary GLU pyramidal neuron (which
now is the third neuron in the series from the top) causing it to lower its
firing rates. This loss of GLU tone at this second GLU neuron is normal.
The fourth neuron is dopaminergic and fires at a normal rate and without
positive psychotic symptoms. When this circuit is optimal or controlled it
avoids generation of positive schizophrenia symptoms allowing the correct
amount of DA activity to occur. This creates a normal GLU-GABA-GLU-DA
neurocircuit loop responsible for maintaining an appropriate, non-psychotic
state. (B) Abnormal GLU-GABA-GLU-DA Neuronal Circuitry and the NMDA
Receptor Hypofunction Hypothesis. The cortical brainstem glutamate
projection in this image is compromised, or defective, in theory by less
active, or suboptimal NMDA receptors. Projection starts again at the top in
the frontal cortex and leads ultimately to the mesolimbic dopamine
pathway again. The fully functioning primary GLU neuron fires upon a
GABA interneuron which now has poorly functioning NMDA receptors
situated on it. The GABA interneuron no longer fires adequately and is
hypo- or under functioning. This resultant loss of GABA activity will cause
the secondary GLU neuron now to abnormally increase its firing rates. This
excessive GLU tone now impinges on the DA mesolimbic pathway directly
stimulating firing and causing DA neuronal activity to be excessive. This
now generates psychotic positive symptoms of schizophrenia. This
abnormal GLU-GABA-GLU-DA neurocircuit loop now may explain the
NMDA receptor hypofunction hypothesis of schizophrenia and possibly be
the cause of the older Dopamine Hypothesis (Stahl, in press).
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in this paper, the authors will try to merge all accounts in order
to allow the reader to think through the possible genetic origins
of schizophrenia symptoms and how these phenotypic symptoms
may emerge at the onset of this severe and persistent psychiatric
disorder.
In regards to the negative symptoms of schizophrenia, another
GLU neurocircuit must be examined (Figure 3). The cortical
brainstem glutamate projection has sub-circuits that are less direct
and do involve two series of GABA interneurons that impact upon
VTA DA neurons whose purpose it is to ascend back to the dor-
solateral prefrontal cortex (DLPFC) and ventromedial prefrontal
cortex (VMPFC). These circuits should provide sufficient activity
for alertness, concentration, emotional, and executive function-
ing. These abilities are often lost, or deficient in schizophrenia,
and are noted as being negative symptoms (Figure 2). A loss of
DA tone in this circuitry or a change in GLU tone that drives the
final DA pathway may create underactivity and inefficient per-
formance in the DLPFC/VMPFC allowing negative symptoms to
develop (Figure 5). Theoretically, if a patient has inherited genes
which code for abnormal proteins that impact by lowering initial
GLU tone or activity in these circuits, then patients may become
hypofrontal with less cortical DA activity and negative symptoms
could develop as well. This type of circuit could become defective
due to abnormal GLU NMDA receptors sitting on GABA interneu-
rons, or any other impingement on the circuit that would result in
final DA common pathway changes further downstream.
In conclusion for this first section, the basic dopamine and glu-
tamate neuropathways have been reviewed in order to alert the
reader as to the current, and most accepted, individual theories
behind the development of schizophrenia symptoms. They have
been simplified and by using adult learning techniques (visuo-
spatial processing by use of Figures, planned redundancy instead
of rote memorization, mnemonics, associations between texts-
figures-verbal constructs, etc.) ideally will be easier to recall and
recognize factually. Later in this paper, these circuits will need to be
remembered and referred to in order to understand how genetic
findings and protein abnormalities might lead to the dysfunction
of these neurocircuits and development of schizophrenia symp-
toms. For the more advanced, neuroscience or neuroanatomic
reader, this simple theoretical material may be made more com-
plex by reviewing the extensive work by Carlsson et al. (1999)
and the following figures may represent the greater complexity of
the neuroanatomic basis of the dopaminergic and glutamatergic
hypotheses of schizophrenia (see Figures 6 and 7).
FIGURE 5 | (A) Normal GLU-GABA-GLU-GABA-DA Neuronal Circuitry and the
NMDA Receptor Hypofunction Hypothesis for negative symptoms. The
cortical brainstem glutamate projection pathway may be involved here as well,
and the circuitry involved in generating negative symptoms of schizophrenia is
one step more complex. A similar relationship exists in the first three steps
with a primary GLU neuron, a GABA interneuron, and a secondary GLU
neuron interacting similar to Figure 4A. Next however is a synapse further
down in the midbrain with yet another GABA interneuron which impinges
upon DA neuronal projections that proceed back to the frontal cortex. Again,
with normal psychiatric functioning, this circuit is balanced and enough DA is
projected to the frontal cortex to avoid any negative symptoms. The circuit
has changed from GLU-GABA-GLU-DA to one of GLU-GABA-GLU-GABA-DA
and it has an extra step. (B) suggests this abnormality may cause negative
symptoms. In schizophrenia, a loss of NMDA activity again may be a
reasonable explanation for negative symptom development. Here, good GLU
tone in the primary GLU neuron impacts dysfunctional NMDA receptors
situated on the first GABA interneuron (same as noted for positive
symptoms. . .). GABA tone is lost in the absence of GLU stimulation and the
secondary GLU neuron again becomes hyperactive. Different from positive
symptom generation, this secondary GLU neuron impinges upon yet another
GABA interneuron and this interneuron is now stimulated by high GLU tone
thus releasing much higher GABA concentrations. This increase in GABA now
causes final pathway DA neurons originating in the midbrain to be inhibited
and fire less. This DA mesocortical pathway is now under active and unable to
supply the frontal cortex with adequate DA and hypofrontality and negative
symptoms occur (Stahl, in press).
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FIGURE 6 | Psychotogenic pathways vicious circle (left). Schematic
diagram illustrating potential psychotogenic pathways and sites of action of
psychotogenic and antipsychotic agents. The striatal complexes (STR, the
centrally located circle) are composed of the dorsal and ventral
striatum/pallidum. The striatum receives glutamatergic inputs from all parts of
the cerebral cortex as well as serotonergic, dopaminergic, and noradrenergic
inputs from the lower brainstem. Amphetamine and phencyclidine (PCP) are
supposed to be psychotogenic by enhancing on striatal dopamine release and
blocking NMDA receptors, respectively. These actions are partly located in the
(limbic) striatum, partly in other sites. For example, PCP may act by blocking
cortical NMDA receptors as well, e.g., in the hippocampus, as indicated in the
figure, leading to reduced tone in corticostriatal glutamatergic pathways. KEY:
CTX cortex, STR striatum, SN substantia nigra, VTA ventral tegmental area
[With Permission Carlsson et al. (1999) and Biological Psychiatry].
GENETICS PRIMER FOR THE GLUTAMATE PATHWAYS
INVOLVED IN SCHIZOPHRENIA
Accepting that the Dopamine Hypothesis is the final common
pathway to schizophrenia symptom development and the com-
plimentary concept that under functioning NMDA receptors or
malfunctioning glutamate circuitry is to blame for the ultimate
schizophrenia DA abnormalities and symptoms, it now makes
sense to better explore how, or why, the GLU system might
become dysfunctional in the first place. Again, patients inherit
genes that code for proteins. If the gene is mutated or abnormal,
then an abnormal protein is created and mass produced. If any
of these proteins affect, or are in the vicinity of the GLU path-
ways, (Figure 3) then the GLU system may falter and change its
overall tone. The downstream effect may be to increase DA in
the mesolimbic system creating positive symptoms or to lower
its activity in the mesocortical symptom allowing for negative
symptoms to occur (Stahl, 2007a, 2008).
The NMDA receptor itself is ubiquitous in the CNS and is a key
factor in promoting glutamatergic neuronal activity throughout.
It is comprised of several small receptor subunits, any of which,
if altered by genetic mutation, might alter NMDA activity leading
to schizophrenia symptoms. As outlined above, any disruption,
making NMDA receptors less active may ultimately account for the
genesis of both positive and negative symptoms of schizophrenia
(Stahl, 2007b).
NMDA receptors have a well defined three dimensional struc-
ture, and they form heterotetramers between two NR1 and two
NR2 type subunits. This forms a pore at the center which is a cal-
cium influx channel (Furukawa et al., 2005) that allows neuronal
depolarization and activation. NR3 A and B subunits have also
been discovered and actually cause NMDA receptors to become
less active or insensitive (Sobolevsky et al., 2002). In theory, genetic
mutations coding for the protein structure of NR1 or 2 subunits,
if making them less sensitive or hypoactive or those making the
NR3 A or B subunits more sensitive or more active, might actually
dampen NMDA receptor channel opening, allowing less calcium
influx. This hyperpolarizing loss of activity might impinge on
the GLU-GABA-GLU or GLU-GABA-GLU-GABA circuits out-
lined previously. The dysfunctional NMDA receptors, sitting on
GABA interneurons in this neurocircuitry may allow for dysfunc-
tional downstream DA activity in final common pathways to create
positive or negative symptoms respectively.
The gene, GRIN1, codes for the NR1 NMDA receptor sub-
unit and GRIN1 gene abnormalities are a key research interest as
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FIGURE 7 | Specific neurocircuitries of the basal ganglia. In this figure the
striato-pallido-thalamic pathways are detailed. Among these, the top and
bottom pathways drawn with thick lines contain three gabaergic neurons and
are referred to as “indirect” pathways. The pathway in between contains two
gabaergic neurons and is referred to as “direct.” Key: SN, substantia nigra;
VTA, ventral tegmental area; STN, subthalamic nucleus; Glu, glutamate; Ach,
acetylcholine; DA, dopamine [With Permission Carlsson et al. (1999) and
Biological Psychiatry].
a susceptibility gene for schizophrenia. Mice lacking NR1 sub-
units (gene knock-out mice) exhibit signs that mimic human
schizophrenia symptoms (Mohn et al., 1999; Halene et al., 2009).
NMDA receptors most often consist of an NR1 subunit (coded
by the GRIN1 gene) plus one of the four types of NR2 subunits
(GRIN2A, GRIN2B, GRIN2C, and GRIN2D genes). The two sub-
units of an NMDA receptor may allow for varying functions, as
the NR1 subunit possesses the characteristic ion channel prop-
erties but the specificity regarding how the NMDA receptor will
ultimately function and react is derived from the NR2 subunits
housed in the receptor complex. In this manner, NMDA receptors
with different functional capacities may be situated in the brain
in order to make neurocircuits more, or less active (Moriyoshi
et al., 1991; Hollmann and Heinemann, 1994; Nakanishi and Masu,
1994). Summarizing a lengthy evidence base regarding NR1 sub-
unit genetics, there are mixed outcomes showing possible NR1
mutations leading to, or protecting against, the development of
schizophrenia. Low NR1 expression due to GRIN1 mutations likely
affords low NMDA activity. By re-reviewing Figure 4, notice that
these mutations may provide a low level of NMDA activity, and
if this occurs at GABA interneurons in the GLU-GABA-GLU cir-
cuit, then DA excess and psychotic symptoms may occur if the
mutated NMDA receptors reside in the cortical brainstem gluta-
mate projection pathway. Likewise negative symptoms may occur
if the cortical brainstem glutamate projections are compromised
in the GLU-GABA-GLU-GABA circuit (Figure 5).
GRIN2A is the gene that codes for the NR2A subunit. These
often appear preferentially in the frontal cortex and increase in the
teen years (Watanabe et al., 1993; Mohrmann et al., 2000), uncanny
in a clinical sense, as this age often heralds the onset of schizophre-
nia. Mice lacking the equivalent of the GRIN2A gene cause abnor-
mal mouse behaviors similar to those observed in animal model
schizophrenia (Miyamoto et al., 2001). Literature reviews support
a stronger evidence base regarding NMDA receptor hypofunc-
tioning related to abnormal GRIN2A genetic vulnerabilities when
compared to GRIN1A. NR2B subunit genetic data suggests mixed
results in regards to its conveying risk for schizophrenia. Stronger
data may actually support an interaction between these genes, i.e.,
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GRIN1A plus GRIN2B, and the interactions between abnormal
genes and their resultant proteins may actually convey greater risk
for schizophrenia than any single gene alone (Williams et al., 2002;
Loftis and Janowsky, 2003; Qin et al., 2005; Tang et al., 2006).
There also exist genes that code for proteins, outside of the
NMDA receptor complex that may be involved in the etiology
of schizophrenia. These proteins may either directly impact the
functioning of the NMDA receptor itself, making it hypoactive in
nature, or these proteins may cause a dampening of GLU neu-
ronal activity with the same net effect of allowing terminal DA
abnormalities in the GLU-GABA-GLU-DA or GLU-GABA-GLU-
GABA-DA circuit to cause positive and negative symptoms. For
example, a calcineurin gene codes for an NMDA catalytic subunit
and rodents missing this gene will have lower (hypofunctioning)
NMDA receptor activity and exhibit psychotic model symptoms
(Gerber et al., 2003; Miyakawa et al., 2003). A mutated neuregulin-
1 (NRG1) gene’s abnormal protein may also contribute to poor
NMDA functioning in rodent and human models (Fischbach and
Rosen, 1997; Ozaki et al., 1997; Stefansson et al., 2002, 2003; Hahn
et al., 2006). Neuregulin-1 codes for a protein that is required for
normal GLU neuron dendritic spine formation. This allows for
normal and efficient GLU neurotransmission and synapse forma-
tion in the GLU circuits discussed in Figure 3. Poorly functioning
neuregulin-1 then would lead to diminished GLU neurotrans-
mission regardless of NMDA receptor capabilities and secondary
DA excesses through the GLU-GABA-GLU-DA circuitry yielding
positive schizophrenia symptoms.
The NMDA receptor is not the only GLU receptor in the CNS.
The non-NMDA ionotropic glutamate receptor kainate-3 gene
(GRIK3) codes for glutamate kainite receptors and certain muta-
tions here may pose a possible risk for schizophrenia (Begni et al.,
2002). Metabotropic (non-NMDA, non-ligand gated channel)
glutamate receptors also exist and their proteins are encoded by
the genes GRM2, GRM5, GRM7, and GRM8. Of these, the GRM5
mutation has revealed the most significant results (EmDevon et al.,
2001).
Gene G72 codes for a protein that interacts with d-amino
acid oxidase enzyme which oxidizes d-serine that usually activates
NMDA receptors making them more efficient. G72 mutations
might allow for underactive NMDA receptor activity by lowering
this enzymatic activity (Chumakov et al., 2002). DTNBP1 (dys-
trobrevin binding protein 1) codes for dysbindin proteins that
are noted to be reduced in the hippocampi and likely frontal
lobes of schizophrenia patients. Altered expression of dysbindin
likely lowers the activity of lysosome related organelle complexes
(BLOC-1) which may lead to abnormal protein distributions in
schizophrenia brains. Therefore, dysbindin may influence and
cause excitotoxic GLU release increasing neuronal cell death. A
reduction in dysbindin activity due to mutations might lead to
a hypoactive glutamatergic system as GLU neurons die and are
pruned allowing a global GLU hypofunctioning to occur, again
regardless of NMDA status (McClintock et al., 2003; Talbot et al.,
2004). Akt1 genes code for protein kinase B and are needed for ade-
quate dysbindin functioning. Mutations of Akt1 may subsequently
cause poor dysbindin activity and ultimately less glutamatergic
tone (Emamian et al., 2004). RGS4 coded proteins are decreased
in the prefrontal cortex of schizophrenic patients and mutations
may alter G protein mediated signaling via DA, metabotropic
GLU, and muscarinic cholinergic receptors. Again, a mutation
here does not directly impact NMDA receptors, but would dimin-
ish metabotropic GLU receptor activity. This metabotropic input
loss, next lowers NMDA receptor activity and lowers GLU tone
with the final common pathway being exhibited by DA pathway
abnormalities (Chen et al., 2004; Morris et al., 2004). Serine race-
mase (SRR) enzyme converts l-serine to d-serine, and the latter is
a co-agonist of the glycine site of NMDA receptors. NMDA recep-
tors require glycine activity to become fully active, depolarize, and
provide optimal neuronal firing. d-Serine also facilitates NMDA
firing in a similar manner. Mutations allowing low SRR activity
would lower the co-agonist properties, thus lowering the ability of
NMDA receptors to be appropriately active. This is another level
of potential GLU circuitry hypofunctioning (Morita et al., 2007).
Finally, in the CNS, nitric oxide (NO) has been shown to influ-
ence the release of neurotransmitters, learning, memory, and neu-
rodevelopment (Maia de Oliveira et al., 2011) by facilitating neu-
ronal maturation and synaptogenesis. Disturbances in NO release
could interfere with both the maturation of cortical neurons and
the formation of viable synaptic connections, in accordance with
the neurodevelopmental hypothesis of schizophrenia and even
during normal synaptic pruning in adolescence and synaptic plas-
ticity into adulthood. Genetically, the promoter region of NO
synthase-I (encoded by the gene NOS1), has been studied in
regards to cortical glutamate transmission and been associated
with schizophrenia symptoms (Reif et al., 2011). Typically, NOS
will generate NO gas, a neurotransmitter, that ultimately functions
to enhance GABA interneuron tone and thus lower secondary
glutamate neuronal activity. This may protect frontal cortical neu-
rons from excitotoxic destruction. Schizophrenics with specific
NOS1 risk alleles (rs41279104 AA/AG) when studied by functional
imaging showed slower dorsolateral cortical functioning consis-
tent with hypofrontal negative symptoms. This may occur as this
risk gene lowers NOS1 production and secondarily NO levels in
the cortex. This causes GABA interneurons to lose tonic firing,
lowering of inhibition upon secondary glutamate neurons that
may now promote excessive glutamate activity, neuronal destruc-
tion, and hypofrontality. Deutsch et al. (1997) conducted a small,
open label study using methylene blue to alter the NO pathway and
found modest improvements in test subjects with schizophrenia
possibly confirming this theoretical model translationally.
All of these aforementioned genes and their protein products do
not directly affect NMDA receptor functioning by altering NMDA
subunits, but may lower GLU tone in GLU neurons allowing the
same downstream effects and schizophrenia symptoms as if the
NMDA receptors themselves were hypofunctioning. The above,
gene-laden paragraph should lead the reader to the conclusion
that there is not one gene that causes schizophrenia but possibly
several that may impact the GLU neurocircuitry and if many of
these genes are inherited then the patient now has an increased
risk to develop schizophrenia. This further alerts that reader that
the Dopamine Hypothesis was too simple. It is clear that the D2
receptor antagonists, first and second generation antipsychotics,
are modest at best at reducing positive symptoms and very poor at
lowering negative symptoms. Schizophrenia development is likely
driven by neurodevelopmental, neurodegenerative, and functional
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neurotransmission abnormalities making the etiology of schizo-
phrenia more complex than the dopamine hypothesis even when it
is augmented and elaborated by way of the glutamate hypothesis.
In summary, the final common pathway of schizophre-
nia symptom development embodies the Dopamine Hypothesis
where too much limbic DA allows for positive symptoms and
too little frontocortical DA allows for negative symptoms. This
is likely the tip of the iceberg in that this effect is superficial but
may not fully describe or explain what is beneath. The NMDA
Receptor Hypofunctioning Hypothesis looks a bit deeper and sug-
gests that faulty NMDA receptors upstream from the DA pathways
are the actual cause of the Dopamine Hypothesis. Weak NMDA
receptors allow DA excesses to occur in some neurocircuits and
deficiencies in others, thus promoting schizophrenia symptoms.
Outside of the basic education of these two complimentary expla-
nations regarding the possible etiology of schizophrenia, this paper
sought to increase the acceptance of the idea that the NMDA
receptors may be key in their own hypothesis, but more glob-
ally, any genetic mutation coding for proteins that might impact
and cause hypofunctioning anywhere along certain GLU pathways
and neurocircuitry may have the same effect as inheriting hypo-
functioning NMDA receptors alone. This corollary to the NMDA
receptor hypothesis then would suggest that poor glutamatergic
tone derived from any source may next lead to the final com-
mon pathway of the Dopamine Hypothesis. The next, and final
section of this paper will utilize this basic science knowledge and
translationally review potential new schizophrenia treatments.
FUTURE TREATMENTS
DIRECT ACTING NMDA RECEPTOR AGONISTS
These agents are analogs for endogenous glycine. Using these
to increase synaptic concentration of co-agonists for the NMDA
receptor should increase NMDA receptor activity. The net effect is
greater glutamatergic tone which ideally rectifies the final common
pathway of DA neurocircuitry dysfunction. d-Cycloserine is one
of the most common agents studied so far and results are equiv-
ocal at best. More recently, one of the largest scale, multicenter
studies (CONSIST) showed that neither glycine nor d-cycloserine
separated from placebo in a randomized trial design in schizophre-
nia patients suffering from negative symptomatology (Buchanan
et al., 2007). Meta-analytically, Tsai and Lin (2010) attempted to
evaluate glutamate-based treatments for schizophrenia and ana-
lyzed 26 studies meeting descriptive stringent trial design criteria
and suggest that GLU manipulating agents can be effective for
both positive and negative symptoms. The most robust effect size
was noted for treating depressive affective symptoms, negative
symptoms, and finally positive symptoms. Full NMDA receptor
agonists, glycine and d-serine, appeared to be most effective in
these clinical symptom areas but partial agonist, d-cycloserine,
was not. All agents were found to be well tolerated.
GLYCINE TRANSPORTER 1 INHIBITORS
Glycine transporters allow reuptake of glycine and when removed
from the synapse, this co-agonist cannot facilitate further NMDA
activity. Similar to SSRI for depression, blocking these transporters
allows endogenous glycine to increase in synaptic concentration
fostering greater NMDA activity to overcome the proposed NMDA
receptor hypofunctioning postulate. Sarcosine is an experimental
agent with this property. When used as adjunctive therapy with an
approved antipsychotic agent, sarcosine has been shown to sep-
arate from placebo and has been validated in a few studies (Tsai
et al., 2004; Lane et al., 2010). These agents appear to directly
improve GLU tone and may have the ability to improve schizophre-
nia in a manner supporting the NMDA Receptor Hypofunctioning
Hypothesis.
KYNURENINE PATHWAY AGENTS
In the CNS, tryptophan is metabolized and degraded into several
metabolites that may inhibit the glutamate neurocircuitry at the
level of the NMDA receptor. Specific metabolites of tryptophan
in this pathway include: quinolinic acid which is an excitotoxic
NMDA receptor agonist, 3-hydroxykynurenine which is a free-
radical generator, and kynurenic add (KYNA) which is an antag-
onist at glutamate receptors. All of these might impair glutamate
neurocircuitry and allow for schizophrenia symptoms to develop.
Findings in schizophrenia show elevated KYNA which specifically
blocks the glycine site on NMDA receptors (Erhardt et al., 2009)
and may be more involved in the generation of negative symp-
toms (cognition, executive dysfunction). Interestingly, KYNA lev-
els increase after infection. Neurodevelopmental theories of schiz-
ophrenia postulate that infections in utero or infancy may lend risk
to developing schizophrenia. Prospective glycine agonists noted
above may be useful if a schizophrenic could be identified as having
excesses in KYNA, as competition at the NMDA receptor glycine
site may be improved. Translationally, KAT II (Kynurenine amino-
transferase: the enzyme responsible for converting tryptophan into
KYNA), could be blocked or antagonized in order to lower KYNA
levels and improve NMDA functioning. COX-2 inhibitors (anti-
inflammatory agents) could be the initial or prototypical agents
mechanistically as they lower KYNA levels.
mGluR 2/3 PRESYNAPTIC RECEPTOR AGONISTS
In some GLU pathways, secondary downstream GLU neurons are
actually hyperactive with increased tone. This situation is noted in
the NMDA Receptor Hypofunction Hypothesis when the primary
GLU neuron is active, but its GABA interneuron has ineffec-
tive NMDA receptors and the GABA interneuron will not fire
and appropriately inhibit a secondary GLU neuron effectively.
This secondary GLU neuron is hyperactive and likely allows DA
abnormalities consistent with the Dopamine Hypothesis. Perfectly
situated, mGluR 2/3 receptors are typically autoreceptors used to
diminish GLU tone. Here, in this specific situation, increasing their
tone with an agonist drug would seek to lower the abnormally
high GLU firing in these secondary GLU neurons. LY2140023 is an
experimental compound that is an mGluR 2/3 receptor agonist and
was recently studied in schizophrenia in a Phase 2 trial comparing
several dose strengths versus an active antipsychotic comparator,
olanzapine, and placebo. Neither the experimental drug, nor the
approved atypical antipsychotic separated from placebo making
interpretation of results negative. The placebo rate was quite high
for a schizophrenia study and four subjects suffered seizure-like
activity (Kinon et al., 2011). A previous, smaller study versus
placebo did show effectiveness in lowering positive and negative
symptoms (Patil et al., 2007).
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NEUROPROTECTIVE AGENTS
Minocycline, an antibiotic, has gained some evidence base in the
literature regarding refractory schizophrenia treatment as it may
treat negative symptoms. Outside of its antibiotic effects, it is felt
to inhibit microglial activation, decrease NO synthase induced
apoptosis of neurons, and possibly positively modulate the GluR1
subunits of AMPA glutamate receptors. AMPA receptors were dis-
cussed only briefly above, but their dysfunction may also lead to
schizophrenia symptoms (Kiss et al., 2011). Glutamate neurocir-
cuitry disruption may occur in the thalamus, more so than the
cortex where dysfunctional AMPA receptors reside. AMPA mod-
ulators have initial data in human schizophrenia trials suggesting
improved long term potentiation rates in hippocampal struc-
tures where memory and cognition findings improved secondarily
(Wezenberg et al., 2007). Minocycline may have its mechanism of
action locally in these non-cortical CNS areas. Therefore, minocy-
cline does not have a direct action on NMDA glutamate receptors,
but may influence AMPA receptors that secondarily influence
NMDA receptors and improve their activity levels theoretically
in schizophrenia (Chaves et al., 2009).
N -acetyl cysteine (NAC) as a prescription is used as a mucolytic
agent in infants for respiratory distress but is gaining increased
research data and clinical use as a psychotropic. Mechanistically,
NAC increases CNS cysteine levels that regulate neuronal intra-
and extracellular exchange of glutamate through a shared trans-
porter with glutamate. These transporters are mostly located on
glial cells where cysteine is taken up and glutamate is released
into the extracellular space. Increased free glutamate next may
be able to increase the firing of inhibitory metabotropic gluta-
mate receptors resting on glutamate neurons effectively lowering
the net, overall release of glutamate (Dean et al., 2011). This
may lower NMDA excitotoxicity and preserve balance between
the dopamine and glutamate neuropathways. Similar to minocy-
cline, negative schizophrenia symptoms appear to preferentially
improve in regards to initial studies’ findings.
CONCLUSION
Clinicians have treated schizophrenia since the 1950s assuming
that DA excess in mesolimbic pathways was the cause of pos-
itive symptoms and DA deficiencies in the mesocortical path-
ways allowed for negative symptoms to develop. This Dopamine
Hypothesis likely holds true for certain patients suffering from
schizophrenia as perhaps these individuals inherited genes for DA
receptors, reuptake pumps, metabolic enzymes, etc. that afforded
them hyperactivity or hypoactivity in these pathways causing
their schizophrenia to develop. If these abnormalities were the
only cause or etiology for schizophrenia then currently avail-
able antipsychotic agents should be remarkably more effective
than they currently are. Educators in psychopharmacology have
likely oversimplified their ideas surrounding the pathophysiol-
ogy of schizophrenia by focusing only on DA mechanisms of
illness. The next most robust hypothesis is that discussed in detail
above, where hypofunctioning glutamate NMDA receptors are to
blame ultimately for DA activity variances which ultimately cause
DA based positive or negative symptoms. The authors attempt
to convey that focusing only on NMDA receptor hypotheses is
also likely too simple. In theory, any genetic mutation that causes
a change in functioning of certain GLU neuroanatomic path-
ways may achieve the same effect as having ineffective NMDA
receptors in that abnormal downstream DA activity can occur at
several different neuroanatomic sites causing schizophrenia symp-
toms to develop. Over the next several years, drug compounds
focusing more on GLU systems may yield helpful treatments for
schizophrenia patients.
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